I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

According to GLOBOCAN 2012, carcinoma of the oral cavity is the third-most common cancer in India.\[[@ref1]\] It is the most common cancer in males and the third-most common nongynecological cancer in females after breast and colorectal cancers.\[[@ref1]\] In our institute, it was the third-most common solid malignancy encountered in 2016.

The burden of oral cavity cancer is significantly higher in India when compared to the West with 70% of our patients presenting in locally advanced stages (AJCC Stage III--IV) where chances of cure are dismal.\[[@ref2][@ref3]\] Five-year survival rates are usually around 20%.\[[@ref4]\] These patients often have poor general condition, poor nutritional status, and other comorbidities making curative treatments difficult.

Various treatment options are available for these patients. Extensive surgical treatment in patients with large tumors often results in disfigurement, difficulties in speech, and feeding and as a result, poor quality of life (QOL) with little survival benefit. Concerns of tolerability and toxicity with suboptimal response rates make chemotherapy an unpopular treatment option. Palliative radiotherapy has now become a standard palliative modality for symptom management in most areas of the human body. Its' role in locally advanced head-and-neck carcinoma has been established already by a number of clinical studies.\[[@ref4][@ref5][@ref6][@ref7][@ref8][@ref9]\] It is common practice to offer patients curative anti-cancer therapy even in advanced malignancies in the hope that it would maximize local control and cure. However, a significant proportion of these patients default treatment and are noncompliant to such protracted schedules.

In India, the absence of supportive care and nutritional support results in poor compliance with about 30% being lost to follow-up.\[[@ref9]\] Intensive curative schedules in such patients make little sense, and the aim should be to identify a schedule which provides effective tumor regression and symptom palliation with acceptable side effects in the minimum possible time.

A standard dose-fractionation scheme is yet to emerge in this setting.\[[@ref10]\] A dose of 52.5 Gy in 15 fractions was a novel dose fractionation regimen investigated by us in this subgroup of patients. It had multiple advantages including a near tumoricidal dose of 59 Gy equivalent dose in 2 (EQD2) and a shortened overall treatment time of 19 days. Keeping in mind that an improvement in QOL is the probably the first and foremost intent of treatment in palliative oncology, we used this fractionation regime to assess the impact of palliative radiotherapy on QOL and used the European Organization of Research and Treatment of Cancer (EORTC) H and *N* 35 and QLQ C30 questionnaires for the same.\[[@ref11][@ref12]\]

The primary objective was to assess the effect of this hypofractionated, palliative conformal radiotherapy regimen of 52.5 Gy in 15 fractions on QOL in patients with late-stage oral cavity cancer using the EORTC QLQ-H and N35 questionnaire with specific attention to pain and mouth opening subscales (in accordance with the most common symptoms in the patient population).

The secondary objective was to assess the general QOL using the EORTC QLQ-C30 and other parameters in the QLQ-H and N35 questionnaires. Other secondary objectives were to assess the median survival, the response rates (using Response Assessment Criteria in Solid Tumors-RECIST guidelines 1.1), acute and late toxicity during radiation therapy -- using Radiation Therapy Oncology Group (RTOG)/Common Terminology Criteria for Adverse Events (CTCAE) grading and compliance to the treatment regimen.\[[@ref13][@ref14]\]

S[UBJECTS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
================================================

Inclusion and exclusion criteria {#sec2-1}
--------------------------------

Patients with biopsy-proven squamous cell carcinoma of the oral cavity of stage IVA--IVC who were not fit for standard/curative treatment and with no previous history of any anti-oncological treatment or the presence of cancer in any other part of the body were eligible for the study. Pregnant women and those with any medical condition precluding radiotherapy were excluded from the study. Patients of age 18--80 were only considered for the trial.

Rationale for the selected regimen {#sec2-2}
----------------------------------

The selection of 52.5 Gy in 15 fractions was guided by multiple factors. It helped us use a near tumoricidal dose of 59 Gy EQD2 (α/β =10) and the delivery of the same in a relatively shorter duration of around 20 days. This would also prevent accelerated repopulation and shorten the hospital stay of patients. Late toxicities though expectedly higher (68 Gy EQD2 with α/β of 3) would probably be of secondary importance due to the short life span of these patients. The use of conformal techniques would help us control the toxicities further. Finally, a hypofractionated regimen would be logistically better in a center like ours with a heavy patient load.

Study procedure {#sec2-3}
---------------

Forty-eight patients who visited the radiotherapy OPD in RCC, JIPMER from August 2015 to July 2017 and satisfied the inclusion and exclusion criteria were recruited into the study. Twenty-eight patients were started on radiotherapy with the others defaulting treatment due to reasons such as disease progression, anxiety, and poor general condition with 25 completing the scheduled course.

Pretreatment evaluation included a biopsy, necessary imaging, hematologic investigations, and a dental evaluation. Performance status (PS), feeding status, and symptom burden were also evaluated. All patients were optimized before radiotherapy. EORTC QLQ C30 and H and N 35 questionnaires were administered to the patients to calculate the baseline QOL score. Patients were started on radiotherapy after computed tomography (CT) simulation, contouring, and planning.

A dose of 52.5 Gy in 15 fractions was prescribed to the planning target volume. Conformal techniques including 3 dimensional conformal radiotherapy, intensity modulated radiotherapy and volumetric modulated arc therapy were used for planning. Late responding tissues were given appropriate constraints after calculating appropriate equivalent dose. Maximum dose (Dmax) to the spinal cord, brainstem, and brain parenchyma was limited to 32.5 Gy, 39 Gy, and 46 Gy, respectively. Dmax to the lens and optic nerve was limited at 7 Gy and 36 Gy, respectively. The mean dose to the contralateral parotid, inner ear, and eyeball was limited at 20 Gy, 34 Gy, and 27 Gy, respectively. Treatment was delivered on the Varian\'s Clinac iX daily for 5 days a week using 6 MV photon beams. Treatment was scheduled and delivered on all weekdays with intent to complete treatment within 19 days.

Toxicity assessment, data collection, and analysis {#sec2-4}
--------------------------------------------------

Patients were assessed for acute toxicities during and immediately after treatment using the RTOG and CTCAE v4.03 criteria. Symptomatic management was administered based on standard guidelines. First follow-up after treatment completion/discharge was done at 1 month. EORTC questionnaires were administered at 2 months to assess posttreatment QOL. A repeat contrast-enhanced CT was taken at 2 months to assess treatment response as per the RECIST criteria. Late toxicities were assessed at 6 months.

Statistics {#sec2-5}
----------

The estimated sample size was 53. The sample size was estimated with an expected improvement of 5 points in EORTC H and N 35 pain subscale (assuming pain to be the most dominant symptom in such patients) with a standard deviation of 12 pretest and 10 posttest, 5% level of significance, and 90% power. Patients were recruited with consecutive sampling.

The median QOL scores of pre- and post-radiation were compared using the Wilcoxon signed-rank test. Survival was assessed using the Kaplan--Meier estimate with the rest of the data represented as counts and percentages. IBMs' SPSS version 19.0 was used for statistical analysis (IBM Corp. Released 2010. IBM SPSS Statistics for Windows, IBM Corp., Armonk, NY, USA).

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Twenty patients did not report for treatment due to factors including disease progression, worsening general condition, anxiety regarding radiotherapy, and monetary concerns. Twenty-eight patients were started on radiotherapy and 25 patients completed the scheduled treatment and have been considered for data analysis. Three patients defaulted radiotherapy after initiation and were lost to follow-up. Six patients expired before the first scheduled follow-up at 2 months. Seventeen patients completed 2 monthly follow-up and were administered the EORTC questionnaires for a second time. They also had a response assessment CT taken at the time. Six patients completed 6 monthly follow-up. Two patient defaulted follow-up posttreatment, the survival data for whom were collected through telephone. Two patients defaulted 6 monthly follow-up due to progressive disease. The necessary data were collected from the attenders of the patients. Follow-up was done till October 2017. At the time of data analysis, 10 patients were alive and under follow-up. Four had completed 6 months of follow-up and 6 had completed 2 months of follow-up. At the time of writing the article, 5 patients were alive and on follow-up.

Baseline parameters {#sec2-6}
-------------------

The study cohort had a median age of 53 with 56% of the patients being females and 80% have buccal mucosa cancer. About 76% had stage IVB malignancy and 24% had stage IVA.

ECOG PS was generally poor with 64% having ≥ 3. No patient had a PS \<2. Almost all the patients (95.2%) were tobacco chewers, whereas one-third (32%) were smokers and 60% were alcohol consumers \[[Table 1](#T1){ref-type="table"}\].

###### 

Baseline parameters of the study participants

  Characteristic                     *n* (%)
  ---------------------------------- ---------
  Sex                                
   Male                              11 (44)
   Female                            14 (56)
  Age                                
   18-40                             2 (8)
   41-50                             7 (28)
   51-60                             12 (48)
   61-70                             2 (8)
   71-80                             2 (8)
  Subsite                            
   Buccal mucosa                     20 (80)
   Lip                               2 (10)
   Hard palate                       2 (10)
   Alveolus                          1 (5)
   RMT, floor of mouth, and tongue   0
  Stage                              
   IVA                               6 (24)
   IVB                               19 (76)
  ECOG PS                            
   2                                 9 (36)
   3                                 14 (56)
   4                                 2 (8)
  Habits                             
   Smoking                           1 (4)
   Tobacco chewing                   17 (68)
   Alcohol                           15 (60)

RMT: Retromolar trigone, ECOG: Eastern Cooperative Oncology Group, PS: Performance status

Symptoms {#sec2-7}
--------

Growth or ulcer was the major symptom in all patients. All patients had pain as a presenting symptom with 80% of the patients having WHO Grade 3 pain. 60% had grade 3 trismus. The other miscellaneous symptoms were ulcer, fistulae, swelling, and puffiness of the face.

Quality of life {#sec2-8}
---------------

The Wilcoxon Signed-rank test was used to compare median scores. There was a universal improvement in QOL scores post radiotherapy \[Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\]. We were most concerned with the pain and mouth opening outcomes, which formed our primary objective. Both showed a significant improvement after radiotherapy (*P* \< 0.001 for pain and 0.040 for mouth opening). The other items in the QLQ-H and N35 questionnaire to show a significant difference in scores were the "speech problems" (*P* = 0.027), "trouble with social eating" (*P* = 0.001), "trouble with social contact" (*P* = 0.01), "teeth problems" (*P* = 0.006), and "felt ill" (*P* = 0.004) subscales. The "dry mouth" subscale along with the "nutritional supplements" and "feeding tube" subscales showed a significantly higher score (less beneficial) in the QLQ-H and N35 questionnaire at 2 months \[[Table 2](#T2){ref-type="table"}\]. This is not surprising as postradiotherapy xerostomia is a well-documented adverse effect. No patient reported weight gain post radiotherapy. Most patients declined to respond to the "Less Sexuality" subscale and results of the same have been omitted from this analysis.

###### 

European Organization of Research and Treatment of Cancer head and neck 35 quality of life scores before and after radiotherapy

  Subscale                      Baseline score   2 months post-RT score   *P*               
  ----------------------------- ---------------- ------------------------ ------ ---------- ---------
  Pain                          50               25-83.3                  25     8.3-58.3   \<0.001
  Swallowing                    16.6             0-50                     16.6   0-50       1.000
  Speech problems               44.4             0-55.5                   22.2   0-55.5     0.027
  Senses problems               33.3             0-50                     16.6   0-50       0.343
  Trouble with social eating    75               33.3-100                 41.6   16.6-75    0.001
  Trouble with social contact   60               6.6-100                  26.6   0-66.6     0.001
  Less sexuality                NA               NA                       NA     NA         NA
  Teeth problem                 33.3             0-66.6                   0      0-66.6     0.006
  Opening mouth                 66.6             0-100                    33.3   0-100      0.040
  Dry mouth                     0                0-33.3                   33.3   0-100      0.005
  Sticky saliva                 33.3             0-66.6                   33.3   0-66.6     0.285
  Coughing                      0                0-66.6                   0      0-33.3     0.131
  Felt ill                      66.6             0-100                    33.3   0-66.6     0.004
  Pain killers                  100              100-100                  100    100-100    1.000
  Nutritional supplements       0                0-100                    100    0-100      0.020
  Feeding tube                  0                0-100                    100    0-100      0.005
  Weight loss                   100              0-100                    100    0-100      0.317
  Weight gain                   0                0-100                    0      0-0        0.317

RT: Radiation therapy, NA: Not available

###### 

European Organization of Research and Treatment of Cancer C30 quality of life scores before and after radiotherapy

  Subscale                   Baseline score   2 months post-RT score   *P*                
  -------------------------- ---------------- ------------------------ ------ ----------- ---------
  Physical functioning       73.3             40-100                   80     53.3-100    0.509
  Role functioning           33.3             0-100                    66.6   33.3-100    0.002
  Emotional functioning      41.6             8.3-83.3                 66.6   33.3-100    0.001
  Cognitive functioning      83.3             33.3-100                 83.3   66.6-100    0.170
  Social functioning         33.3             0-66.6                   50     33.3-100    0.001
  Fatigue                    55.5             0-66.6                   33.3   0-66.6      0.004
  Nausea and vomiting        0                0-66.6                   0      0-66.6      0.170
  Pain                       66.6             33.3-100                 16.6   0-66.6      \<0.001
  Dyspnoea                   0                0-33.3                   0      0-33.3      0.157
  Insomnia                   66.6             0-100                    0      0-33.3      0.001
  Appetite loss              66.6             0-100                    33.3   0-66.6      0.002
  Constipation               0                0-100                    0      0-66.6      0.713
  Diarrhoea                  0                0-0                      0      0-66.6      0.180
  Financial difficulties     33.3             0-100                    33.3   0-66.6      0.006
  Global Health Status/QOL   50               16.6-83.3                66.6   33.3-83.3   0.005

QOL: Quality of Life, RT: Radiation therapy

All functional scale scores showed improvement postradiotherapy. However, only the "role functioning," "emotional functioning," and "social functioning" with *P* values of 0.002, 0.001, and 0.001, respectively, reached significance \[[Table 3](#T3){ref-type="table"}\]. There was a significant improvement in some of the symptom scales, namely "fatigue" (*P* = 0.004), "pain" (*P* \< 0.001), "insomnia" (*P* = 0.001), "appetite loss" (*P* = 0.002), and "financial difficulties" (*P* = 0.006), while others such as "nausea and vomiting," "dyspnea," "constipation," and "diarrhea" showed no significant change. There was a significant improvement in the Global QOL postradiotherapy (*P* = 0.005) \[[Table 3](#T3){ref-type="table"}\].

Survival and response {#sec2-9}
---------------------

The median survival of the population was 5.1 months (15 months for IVA and 4.3 months for IVB). The response rate was 47% (12% complete response, 35% partial response). About 35% had stable disease.

Toxicity {#sec2-10}
--------

Seventy-two percent of the patients had grade 3 acute oral mucositis and 36% had ≥3 acute dermatitis. The severity of acute radiation dermatitis and oral mucositis was expectedly high due to the dose-dense radiotherapy schedule we used. Three patients had treatment breaks due to toxicity. Most patients responded well to supportive care in the postradiotherapy period. At two monthly follow-up no patient had grade 3 mucosal reactions. A total of 3 patients developed oro-cutaneous fistulae -- one before the start, one during and one 2 weeks after radiotherapy. The tract persisted in all three patients. Ten patients developed acute radiation pharyngitis during radiotherapy/immediately after it. All of them had odynophagia to varying degrees, which subsided after symptomatic care. Grade 2 laryngeal toxicity and oral candidiasis were found in four patients each, all of whom responded well to supportive treatment.

Only 5 patients completed 6 months follow-up, the others being too sick to report for assessment and as a result, the data on late toxicity are modest. All patients had grade 2 xerostomia and grade 2 subcutaneous fibrosis. One patient had grade 2 dysphagia. 13 of the 20 patients who were offered Ryle\'s tube feeding accepted the same. All patients with \>3 radiation reactions/inadequate nutrition were referred for in-patient care. Fourteen patients received in-patient care during and in the immediate postradiotherapy period.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Local control and cure rates are disappointing in locally advanced oral cavity cancer. Untreated patients have modest survival rates of around 100 days.\[[@ref15]\] Hypofractionated palliative radiotherapy schedules have shown improvements in QOL and symptomatic burden along with good response rates and acceptable toxicities making them a standard in incurable oral cavity malignancies \[[Table 4](#T4){ref-type="table"}\]. The "Christie Trial" from the Netherlands studying 50 Gy in 16 fractions reported a 77% improvement in pain in patients with a Global health score of 71 in the EORTC questionnaires.\[[@ref5]\] The Agarwal *et al.* study, which used 40 Gy in 16 fractions reported \>50% pain improvement in 78% of patients.\[[@ref6]\] We identified QOL as the most important endpoint in these group of patients as different schedules have shown little improvement in survival and local control over the years. Since buccal mucosa is the most common subsite of cancer of the oral cavity and forms the major subgroup of patients reporting to our OPD, our focus was on this subgroup of patients. Our main objective was to assess QOL scores with respect to pain and mouth opening, two of the most distressing symptoms in this subgroup of patients. Our patients showed a significant improvement in median pain scores 2 months after treatment. The improvement in pain scores was probably a result of good tumor control with all patients reporting an improvement in pain with 59% of the patients reporting \>50% improvement. All patients were prescribed pain killers at the onset of evaluation and adherence to the same was strictly monitored with the help of the Palliative Care Clinic staff. About 68% of the patients were on oral morphine at some stage and 16% were on fentanyl patches.

###### 

Studies of palliative hypofractionated radiotherapy in advanced head and neck cancer

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                            QOL instrument and results                                                                                                                                                                                                                      Dose-fractionation                                           Overall treatment time   EQD2-acute     EQD2-late      Response rate   Median survival         Toxicity (\> Grade 3)
  -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ------------------------ -------------- -------------- --------------- ----------------------- -----------------------
  Our study                        EORTC QLQ C-30 and QLQ - HN 35. Significant improvement in pain, mouth opening, social contact and eating, speech problems, social, role, and emotional functioning, fatigue, insomnia, appetite loss, financial difficulties, and Global QOL   52.5 Gy in 15 fr                                             24 days                  57 Gy          68 Gy          47%             5.1 months              Muco - 72%\
                                                                                                                                                                                                                                                                                                                                                                                                                                               Derm - 36%

  Al-Mamgani *et al*.\[[@ref5]\]   EORTC QLQ C-30 and QLQ - HN 35. GHS of 71                                                                                                                                                                                                       50 Gy in 16 fr                                               22 days                  55 Gy          61 Gy          73%             17 months               Muco - 65%\
                                                                                                                                                                                                                                                                                                                                                                                                                                               Derm - 45%

  Corry *et al*.\[[@ref7]\]        EORTC QLQ - C30. 44% reported improvement in overall QOL                                                                                                                                                                                        42 Gy in 12 fr                                               2-58 days                16-25 Gy       18-55 Gy       53%             5.7 months              Muco - 0%\
                                                                                                                                                                                                                                                                                                                                                                                                                                               Derm - 0%

  Porceddu *et al*.\[[@ref8]\]     FACT - HN. 62% improvement in overall QOL, 67% improvement in overall pain, 76% improvement in ability to work                                                                                                                                  30 Gy in 5 fr with additional 6 Gy boost                     15-18 days               39-48 Gy       54-65 Gy       75%             6 months                Muco - 26%\
                                                                                                                                                                                                                                                                                                                                                                                                                                               Derm - 11%

  Das *et al*.\[[@ref9]\]          FACT- HN. Significant improvement in Social well-being.\                                                                                                                                                                                        40 Gy in 10 fr                                               30 days                  41 Gy          56 Gy          NA              7 months                Muco - 24%\
                                   Improvement in all other subscales - not significant.\                                                                                                                                                                                                                                                                                                                                                      Derm - 3%
                                   HN-specific score showed no significant change                                                                                                                                                                                                                                                                                                                                                              

  Fortin *et al*.\[[@ref16]\]      EORTC PAL C-15 and EORTC QLQ - HN 35. 83% reported improvement in pain scores, 75% in swallowing scores and 58% reported improvement in physical functioning and global QOL at 6 months                                                         25 Gy in 5 fr                                                5 days                   31 Gy          40 Gy          NA              6.5 months              Muco - 7%\
                                                                                                                                                                                                                                                                                                                                                                                                                                               Derm - 0%

  Mohanti *et al*.\[[@ref4]\]      NA                                                                                                                                                                                                                                              20 Gy in 5 fr - upto 70 Gy EQD2 depending on response        5 days                   23 Gy          28 Gy          47%             6.6-13 months           Muco - 62%\
                                                                                                                                                                                                                                                                                                                                                                                                                                               Derm - 14%

  Agarwal *et al*.\[[@ref6]\]      NA                                                                                                                                                                                                                                              40 Gy in 16 fr - upto 50 Gy in 20 fr depending on response   22-26 days               41-50 Gy       44-55 Gy       73%             NA 1 year PFS - 55.1%   Muco - 66%\
                                                                                                                                                                                                                                                                                                                                                                                                                                               Derm - 56%

  Soni *et al*.\[[@ref17]\]        University of Washington. Significant improvement in scores of pain, appearance, activity, recreation, swallowing, mood, anxiety, physical domain, social domain, HRQOL 7 days and overall QOL to various degrees in all the 3 arms             Arm 1-44.4 Gy in 12 fr\                                      Arm 1-44 days\           Arm 1-37 Gy\   Arm 1-60 Gy\   Arm 1%-83%\     Arm 1-11.5 months\      Muco - 37% (1)\
                                                                                                                                                                                                                                                                                   Arm 2-50 Gy in 16 fr\                                        Arm 2-22 days\           Arm 2-55 Gy\   Arm 2-61 Gy\   Arm 2%-80%\     Arm 2-10.5 months\      versus 53% (2)\
                                                                                                                                                                                                                                                                                   Arm 3-40 Gy in 10 fr                                         Arm 3-26 days            Arm 3-44 Gy    Arm 3-56 Gy    Arm 3%-77%      Arm 3-11 months         versus 23%(3)\
                                                                                                                                                                                                                                                                                                                                                                                                                                               Derm - 23%(1)\
                                                                                                                                                                                                                                                                                                                                                                                                                                               versus 40%(2)\
                                                                                                                                                                                                                                                                                                                                                                                                                                               versus 20%(3)

  Laursen *et al.*\[[@ref18]\]     NA                                                                                                                                                                                                                                              52-56 Gy in 13-14 fr                                         43-46 days               48-50 Gy       73-78 Gy       45%             5.4 months              Muco - 24%\
                                                                                                                                                                                                                                                                                                                                                                                                                                               Derm - 15%
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GHS: Global Health Score, QOL: Quality of life, HN: Head and neck, HRQOL: Health-related quality of life, EQD2: Equivalent dose in 2 Gy per fraction, fr: Fraction, muco: Mucositis, derm: Dermatitis, NA: Not available, EORTC: European Organization of Research and Treatment of Cancer

The results from the mouth opening subscale were similarly encouraging with 35% reporting an improvement. The improvement in pain may also have contributed to this end point. Due to paucity of literature on this end point, a standard comparison could not be made.

Other symptom subscales in the QLQ-H and N35 showing a significant improvement \[[Table 2](#T2){ref-type="table"}\] was a vindication of the ability of the radiotherapy schedule and associated supportive care to shrink the visible tumor and improve the oral hygiene. Most patients were found to have inadequate nutrition as a result of the treatment/tumor. Although supportive measures in the form of nasogastric feeding were initiated, no patient reported an improvement in weight with most continuing to have weight loss. Other items to show significant worsening in scores were the "dry mouth," "nutritional supplements," and "feeding tube" subscales \[[Table 2](#T2){ref-type="table"}\]. As xerostomia is well-documented toxicity of radiotherapy, this was not unexpected. The difference in the other two was due to the greater use of feeding tube and nutritional supplements as part of supportive care.

The improvement in functional scales was a direct result of the tumor regression post radiotherapy \[[Figure 1](#F1){ref-type="fig"} and [Table 3](#T3){ref-type="table"}\]. The lack of significant differences in other subscales was probably due to the poor nutritional status and the limited value of the assessed parameter in itself. Further symptomatic improvement was reflected in other subscales \[[Table 3](#T3){ref-type="table"}\].

![(a) A patient with Stage IVA Buccal mucosa cancer before receiving radiotherapy. (b) The same patient showing complete clinical response 2 months after radiotherapy completion](IJPC-25-383-g001){#F1}

The severity of acute dermatitis and mucositis were expectedly high with 36% and 72%, respectively having grade ≥3 radiation reactions. However, this was the by-product of a dose-intense regimen. The three trials closest to ours in terms of total dose and dose per fraction was the Christie trial, the Tata Memorial Hospital (TMH) study and the All India Institute of Medical Sciences (AIIMS) study and had grade 3 mucositis rates of 65%, 66%, and 62%, respectively.\[[@ref4][@ref5][@ref6]\] The corresponding grade 3 skin toxicity was 45.14% and 56%, respectively in these three studies. The Christie group in the three arm randomized trial had 53% grade 3 acute mucosal toxicity and 40% grade 3 skin reactions.\[[@ref17]\] Our results of 36% grade 3 skin toxicity though high was not completely unexpected and was in keeping with the schedule we used and similar to the rates reported in the literature. Even though some trials have reported very minimal toxicity rates using IMRT like the Laursen *et al.*\[[@ref18]\] trial, prolonged overall treatment time and possibly lesser treatment volumes (only 20% with stage IV B) would have also contributed to it. Only six patients could complete the necessary 6 monthly follow-up to record late toxicities, and as a result, the data were not sufficient to draw any meaningful conclusions. However, there were no grade 3 toxicities recorded in any of the patients who completed follow-up.

Twenty patients were offered feeding tube support at some point in the study. Thirteen (65%) patients accepted Ryle\'s tube, while 7 declined the same. All patients continued Ryle\'s tube feeding till the end of the study/their death. The 52% Ryle\'s tube dependence seen in our study was slightly higher than the 29% reported by the Christie trial and 25% reported by the TMH study but was on par with the 42% reported by the Split course trial by Bledsoe *et al.*\[[@ref19]\]

The median survival for the cohort was 5.1 months. This was along expected lines. Most studies have shown survival rates between 5 and 12 months with the Christie scheme study by Al-Mamgani *et al.* being the notable exception. They reported a median survival of 17 months.

Response rates were assessed using the RECIST criteria. Only two other studies, both from Canada and both reporting 82% response rates -- had attempted the same.\[[@ref20][@ref21]\] The study population had 47% overall response rate. This was similar to the Quad Shot trial and the AIIMS study. The local response rates reported in literature varies between 47% and 100% with both the Christie trial and the TMH study reporting response rates of 73%. However, the complete response rates from the Christie trial was 45% compared to the 10% complete response rates reported by the TMH study. Our patients had a complete response rate of 12%. As more than three-fourths of the patients had T4b disease, response rate, similar to the survival data was expected to be modest. Most patients had tumors with significant local extension resulting in very large treatment volumes. The local control of such extensive tumors is often cumbersome as it proved in our case.

The median time to treatment completion in our study was 24 days (range-19--59). Twenty-three patients (48%) defaulted treatment due to toxicities, financial, and social reasons resulting in prolonged treatment times, the progression of the disease, financial concerns, and other reasons. This was higher than the 27% dropout rates in the CMC, Vellore study\[[@ref9]\] and 16% noncompliance rates in the TMH study.\[[@ref6]\] The 89% treatment completion rates after initiation of radiotherapy showed that the study was compatible with this patient subgroup.

C[ONCLUSIONS]{.smallcaps} {#sec1-5}
=========================

The hypofractionated regimen of 5250 cGy in 15 fractions is an acceptable palliative radiotherapy regimen for late-stage oral cavity cancer. Good palliation in terms of pain, mouth opening, speech problems, and social functioning was achieved with this regimen. However, the prolonged periods of palliation we intended to achieve in terms of pain and mouth opening did not come to fruition due to relatively low survival rates. The dismal overall survival rate of 5.1 months was probably due to the inadequacy of dose (BED 59 Gy) and the very advanced stages of the disease the patients had (76% stage IVB). These patients may benefit from newer fractionation schedules, which find an acceptable balance between prolonged tumor control, compliance, and toxicity.
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